A detailed history of Royce & Associates LP transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 22,500 shares of AXSM stock, worth $1.96 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
22,500
Previous 13,000 73.08%
Holding current value
$1.96 Million
Previous $1.05 Million 93.21%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$78.93 - $95.84 $749,835 - $910,480
9,500 Added 73.08%
22,500 $2.02 Million
Q1 2024

May 13, 2024

BUY
$69.39 - $97.64 $902,070 - $1.27 Million
13,000 New
13,000 $1.04 Million
Q3 2021

Nov 10, 2021

SELL
$19.91 - $68.26 $404,173 - $1.39 Million
-20,300 Closed
0 $0
Q2 2021

Aug 06, 2021

SELL
$50.63 - $73.5 $273,402 - $396,900
-5,400 Reduced 21.01%
20,300 $1.37 Million
Q2 2020

Aug 07, 2020

SELL
$49.87 - $98.69 $718,128 - $1.42 Million
-14,400 Reduced 35.91%
25,700 $2.12 Million
Q1 2020

May 12, 2020

SELL
$41.2 - $101.31 $824,000 - $2.03 Million
-20,000 Reduced 33.28%
40,100 $2.36 Million
Q4 2019

Feb 06, 2020

SELL
$16.71 - $106.24 $745,266 - $4.74 Million
-44,600 Reduced 42.6%
60,100 $6.21 Million
Q3 2019

Nov 13, 2019

SELL
$20.24 - $29.16 $202,399 - $291,600
-10,000 Reduced 8.72%
104,700 $2.12 Million
Q2 2019

Aug 12, 2019

SELL
$13.46 - $25.75 $911,242 - $1.74 Million
-67,700 Reduced 37.12%
114,700 $2.95 Million
Q1 2019

May 09, 2019

SELL
$2.63 - $16.34 $394,500 - $2.45 Million
-150,000 Reduced 45.13%
182,400 $2.6 Million
Q3 2018

Nov 13, 2018

SELL
$2.3 - $3.55 $1.28 Million - $1.97 Million
-556,000 Reduced 62.58%
332,400 $1.15 Million
Q2 2018

Aug 09, 2018

SELL
$2.15 - $3.6 $145,340 - $243,360
-67,600 Reduced 7.07%
888,400 $2.84 Million
Q1 2018

May 14, 2018

BUY
$2.35 - $5.6 $176,250 - $420,000
75,000 Added 8.51%
956,000 $2.34 Million
Q2 2017

Aug 07, 2017

BUY
N/A
881,000
881,000 $4.85 Million

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.73B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.